DocStoX is a free AI-powered research platform for Indian equity markets, covering 5,700+ NSE & BSE stocks with prices, fundamentals, 326 financial ratios, shareholding, FII/DII flows, F&O, IPOs, a visual screener and AI stock scoring.

Yes. DocStoX has a free tier covering stock research, the screener, FII/DII data and educational guides, plus a free MCP API tier (50 tool calls/day) for AI assistants. A Pro plan adds higher limits and advanced features.

What data does DocStoX cover?

Every NSE & BSE listed stock (5,700+ instruments): EOD and intraday prices, income statement / balance sheet / cash flow, 326 ratios, quarterly shareholding, promoter pledge, mutual-fund holdings, FII/DII flows, F&O and option-chain data, analyst forecasts, IPOs, corporate actions and news.

Can AI assistants like ChatGPT or Claude use DocStoX data?

Yes. DocStoX runs a public Model Context Protocol (MCP) server at https://mcp.docstox.com/mcp with 94 tools, so Claude, ChatGPT, Cursor and other MCP clients can pull Indian market data directly. Setup and a free key are at https://docstox.com/mcp.

Neutral impactCompany

AstraZeneca Pharma India Limited — Certificate under SEBI (Depositories and Participants) Regulations, 2018

NSE 1 hr ago·26 Oct 2026, 7:25 pm

Astrazeneca Pharma IND LT

AstraZeneca Pharma India Limited has submitted a certificate to the stock exchanges, confirming its compliance with the SEBI (Depositories and Participants) Regulations, 2018. This regulatory filing is a standard administrative requirement for listed companies to ensure their depository and participant accounts are in order.

For investors, this news is largely procedural and does not signal any operational or financial change for the company. It is a routine update meant to maintain transparency and regulatory compliance. While it confirms that the company is adhering to market rules, it does not provide any new information regarding the company's business performance or future outlook.

Investors should treat this as a standard corporate disclosure with no immediate impact on the stock price. To gauge the company's actual performance, it is more important to focus on upcoming quarterly results, new product launches, and overall market trends in the pharmaceutical sector.